Ivana Spasevska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ivana Spasevska has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- June Helen Myklebust
Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway
42 shared publications - Eerika Sahlberg
Applied Tumor Genomics Faculty of Medicine Research Programs Unit University of Helsinki Helsinki Finland
41 shared publications - Iftekhar Chowdhury
Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland
41 shared publications - Kanutte Huse
Department of Cancer Immunology Institute for Cancer Research Oslo University Hospital Oslo Norway
41 shared publications - Leo Meriranta
University of Helsinki, Helsinki University Hospital Comprehensive Cancer Centre and iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland
41 shared publications - Luka Tandarić
Centre for Cancer Biomarkers CCBIO, Department of Clinical Science University of Bergen Norway
41 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S9 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Figure S1 shows KLHL6 expression and its molecular correlates in reactive lymphoid and DLBCL tissues. Figure S2 shows recurrent KLHL6 mutations and their subcellular localization. Figure S3 shows data from affinity-purification mass-spectrometry (AP-MS) interactome analysis of Strep-tagged wild-type KLHL6 in the expansion cell line panel. Figure S4 shows data related to proximity-labeling interactome analysis of KLHL6. Figure S5 shows KLHL6 interactome upon BCR stimulation and the impact of recurrent mutations on BCR levels. Figure S6 shows the impact of KLHL6 constructs on the surface levels expression of the BCR components. Figure S7 shows the impact of KLHL6 constructs on the BCR signaling. Figure S8 shows immunofluorescent analysis and quantification of CD79B staining intensity. Figure S9 shows BANK1 expression in DLBCL.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S9 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Figure S1 shows KLHL6 expression and its molecular correlates in reactive lymphoid and DLBCL tissues. Figure S2 shows recurrent KLHL6 mutations and their subcellular localization. Figure S3 shows data from affinity-purification mass-spectrometry (AP-MS) interactome analysis of Strep-tagged wild-type KLHL6 in the expansion cell line panel. Figure S4 shows data related to proximity-labeling interactome analysis of KLHL6. Figure S5 shows KLHL6 interactome upon BCR stimulation and the impact of recurrent mutations on BCR levels. Figure S6 shows the impact of KLHL6 constructs on the surface levels expression of the BCR components. Figure S7 shows the impact of KLHL6 constructs on the BCR signaling. Figure S8 shows immunofluorescent analysis and quantification of CD79B staining intensity. Figure S9 shows BANK1 expression in DLBCL.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Table S3 shows data from interactome analysis of KLHL6 in B-cell lymphoma cell lines. Strep-tag affinity purification and mass-spec peptide identification (AP-MS).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Table S3 shows data from interactome analysis of KLHL6 in B-cell lymphoma cell lines. Strep-tag affinity purification and mass-spec peptide identification (AP-MS).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Table S5 shows data from the co-localization analysis of KLHL6 and BANK1 and analysis of protein-protein interactions of KLHL6 variants identified with proximity-ligation with C-terminal BioID2 constructs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Table S5 shows data from the co-localization analysis of KLHL6 and BANK1 and analysis of protein-protein interactions of KLHL6 variants identified with proximity-ligation with C-terminal BioID2 constructs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1. from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Table S1 shows molecular and clinical correlates of KLHL6 protein expression.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1. from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Table S1 shows molecular and clinical correlates of KLHL6 protein expression.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Table S2 shows recurrent KLHL6 mutations reported in DLBCL.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Table S2 shows recurrent KLHL6 mutations reported in DLBCL.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Table S4 shows data from the analysis of protein-protein interactions of KLHL6 identified with proximity-ligation with C-terminal BioID2 constructs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Table S4 shows data from the analysis of protein-protein interactions of KLHL6 identified with proximity-ligation with C-terminal BioID2 constructs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Unprocessed Western blots from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Unprocessed Western blots for Figures 1E, 3I, 4E, 4F, 5A, 5S5, 5E, 5F, 5G, 5H, 7D, 7K, S5G, S5H, and S9A
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessUnprocessed Western blots from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Unprocessed Western blots for Figures 1E, 3I, 4E, 4F, 5A, 5S5, 5E, 5F, 5G, 5H, 7D, 7K, S5G, S5H, and S9A
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Table S6 shows a list of resources and reagents used in the study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Table S6 shows a list of resources and reagents used in the study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Complementary interactome screening with Kelch-domain coupled proximity-labeling reveals potential substrates of KLHL6 in B-cell context. A, Schematic representation of proximity-labeling (PL) substrate screening with BioID2 approach for C-terminally tagged KLHL6. B, Volcano plot of the DESeq2 model showing the differentially interacting proteins between BioID2-tagged WT KLHL6 and EmGFP constructs showing only the KLHL6-interacting proteins with a positive log2-transformed fold-change (LFC). Colors as in Fig. 3B. C, Comparison of KLHL6 interactomes obtained with the complementary protein interaction screening methods. Evidence for protein binding by APs (“AP-MS”) and proximity-labeling (“BioID2”) are indicated with LFCs of DESeq2 models with respective EmGFP control pull-downs. Labels indicate proteins with strong evidence by both methods and AP/PL-specific interactors not considered common contaminants in mass spectrometry experiments. D, Summary of identified KLHL6 interactors with the complementary screening methods. E, Western blots showing the impact of KLHL6 expression manipulation at the protein levels of BCR components CD79A, CD79B, and IgH (IgM or IgG) in four different cell lines. Below, bar blots show the quantified protein levels of the BCR components in cells with ectopic KLHL6 overexpression (KLHL6 OE) or KLHL6 silencing (KO, knockout; KD, knockdown) normalized to the total protein levels in relation to their respective controls (EmGFP, sgCTRL, or sh_CTRL). F, Western blots showing the impact of KLHL6 expression manipulation on the protein levels of its proximity interactors BANK1 and LuZP1. Heatmaps show the average quantified protein levels from KLHL6 overexpressing or knockout cells normalized to β-actin in relation to the EmGFP- or sgCTRL-transduced cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Complementary interactome screening with Kelch-domain coupled proximity-labeling reveals potential substrates of KLHL6 in B-cell context. A, Schematic representation of proximity-labeling (PL) substrate screening with BioID2 approach for C-terminally tagged KLHL6. B, Volcano plot of the DESeq2 model showing the differentially interacting proteins between BioID2-tagged WT KLHL6 and EmGFP constructs showing only the KLHL6-interacting proteins with a positive log2-transformed fold-change (LFC). Colors as in Fig. 3B. C, Comparison of KLHL6 interactomes obtained with the complementary protein interaction screening methods. Evidence for protein binding by APs (“AP-MS”) and proximity-labeling (“BioID2”) are indicated with LFCs of DESeq2 models with respective EmGFP control pull-downs. Labels indicate proteins with strong evidence by both methods and AP/PL-specific interactors not considered common contaminants in mass spectrometry experiments. D, Summary of identified KLHL6 interactors with the complementary screening methods. E, Western blots showing the impact of KLHL6 expression manipulation at the protein levels of BCR components CD79A, CD79B, and IgH (IgM or IgG) in four different cell lines. Below, bar blots show the quantified protein levels of the BCR components in cells with ectopic KLHL6 overexpression (KLHL6 OE) or KLHL6 silencing (KO, knockout; KD, knockdown) normalized to the total protein levels in relation to their respective controls (EmGFP, sgCTRL, or sh_CTRL). F, Western blots showing the impact of KLHL6 expression manipulation on the protein levels of its proximity interactors BANK1 and LuZP1. Heatmaps show the average quantified protein levels from KLHL6 overexpressing or knockout cells normalized to β-actin in relation to the EmGFP- or sgCTRL-transduced cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Interrogation of CD79B at the protein level in the discovery set and KLHL6-mutated tumors. P values for comparisons between two groups in box plots are calculated with the Mann–Whitney U test. Individual channels shown for the white dashed areas are shown right to the microscopy images. A, IF microscopy image of a GC in a reactive lymph node showing the highest CD79B intensity in the mantle zone, whereas KLHL6 positivity is restricted to the GC. Scale bar, 100 µm. B and C, Box and dot plots with y-axis showing (B) quantified CD79B intensity and (C) CD79B gene expression (from RNA sequencing) according to KLHL6GC+ IHC (x-axis). D, Box and dot plots of quantified CD79B intensity according KLHL6GC+ IHC phenotype within different molecular subtypes determined by gene expression profiling. E, Representative IF microscopy images of KLHL6GC- tumors showing plasma membrane–like CD79B staining. Sections stained for CD79B, KLHL6, and DNA (DAPI) and images obtained with optical sectioning and 40× objective. Scale bar, 20 µm. F, Oncoprint of patients (columns) with KLHL6 and/or CD79B mutations (n = 23). G, Box and dot plot of CD79B intensity according to KLHL6 BTB domain encoding mutation status. Amino acid changes of all KLHL6 mutations for available cases are annotated, and the presence of CD79B mutations is indicated with a color. H, Box and dot plot showing CD79B intensity according to CD79B mutations with Y197 hot spot considered separately. Color of the dots indicates KLHL6GC IHC status and amino acid changes of CD79B mutations are annotated. I, Representative IF microscopy images of tumors with different KLHL6 mutations co-stained for CD79B, KLHL6, and DNA (DAPI). Images within dashed area indicate additional KLHL6-mutated DLBCL tumors not included in the discovery cohort. Scale bar, 20 µm applies to all images.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
Interrogation of CD79B at the protein level in the discovery set and KLHL6-mutated tumors. P values for comparisons between two groups in box plots are calculated with the Mann–Whitney U test. Individual channels shown for the white dashed areas are shown right to the microscopy images. A, IF microscopy image of a GC in a reactive lymph node showing the highest CD79B intensity in the mantle zone, whereas KLHL6 positivity is restricted to the GC. Scale bar, 100 µm. B and C, Box and dot plots with y-axis showing (B) quantified CD79B intensity and (C) CD79B gene expression (from RNA sequencing) according to KLHL6GC+ IHC (x-axis). D, Box and dot plots of quantified CD79B intensity according KLHL6GC+ IHC phenotype within different molecular subtypes determined by gene expression profiling. E, Representative IF microscopy images of KLHL6GC- tumors showing plasma membrane–like CD79B staining. Sections stained for CD79B, KLHL6, and DNA (DAPI) and images obtained with optical sectioning and 40× objective. Scale bar, 20 µm. F, Oncoprint of patients (columns) with KLHL6 and/or CD79B mutations (n = 23). G, Box and dot plot of CD79B intensity according to KLHL6 BTB domain encoding mutation status. Amino acid changes of all KLHL6 mutations for available cases are annotated, and the presence of CD79B mutations is indicated with a color. H, Box and dot plot showing CD79B intensity according to CD79B mutations with Y197 hot spot considered separately. Color of the dots indicates KLHL6GC IHC status and amino acid changes of CD79B mutations are annotated. I, Representative IF microscopy images of tumors with different KLHL6 mutations co-stained for CD79B, KLHL6, and DNA (DAPI). Images within dashed area indicate additional KLHL6-mutated DLBCL tumors not included in the discovery cohort. Scale bar, 20 µm applies to all images.